新辅助帕博利珠单抗联合加速MVAC方案治疗非尿路上皮型肌层浸润性膀胱癌的2期试验
这项单中心2期试验评估新辅助帕博利珠单抗联合加速MVAC化疗在纯或主要非尿路上皮组织学亚型肌层浸润性膀胱癌患者中的疗效。17例患者入组,最常见变异为鳞状分化。主要终点病理完全缓解率达53%(9/17),降期率59%,≥3级毒性发生率47%,中位随访35个月时2年无事件生存率和总生存率分别为64%和79%。
要点
- 非尿路上皮组织学亚型肌层浸润性膀胱癌对传统治疗反应差且临床试验代表性不足
- 新辅助帕博利珠单抗联合加速MVAC方案取得53%病理完全缓解率和59%降期率
- ≥3级毒性发生率47%,主要归因于加速MVAC化疗
核心结论
- 新辅助帕博利珠单抗联合加速MVAC化疗在非尿路上皮组织学亚型肌层浸润性膀胱癌中显示出非常有前景的疗效。
- 需要更大规模研究进一步优化治疗策略。
研究设计与样本
- 单中心2期临床试验,评估新辅助帕博利珠单抗联合加速MVAC化疗在纯或主要非尿路上皮组织学亚型肌层浸润性膀胱癌患者中的疗效。
- 共入组17例患者,鳞状分化为最常见变异类型。
主要发现
- 主要终点病理完全缓解(pCR)在9/17例(53%)患者中达成。
- 另有1例患者达到ypTisN0,降期率为59%;还有1例达到临床完全缓解。
- ≥3级毒性发生率为47%,主要归因于加速MVAC化疗。
- 中位随访35个月(范围11-48个月)时,估计2年无事件生存率(EFS)为64%(95%CI 32-84%),总生存率为79%(95%CI 47-93%)。
- 初步生物标志物分析未发现基线免疫细胞亚群与pCR或EFS之间存在显著相关性。
临床怎么用
- 对于非尿路上皮组织学亚型的肌层浸润性膀胱癌,可考虑新辅助帕博利珠单抗联合加速MVAC化疗作为治疗选择。
- 治疗期间需密切监测≥3级毒性,尤其是加速MVAC化疗相关毒性。
局限性
- 单中心2期试验样本量小(17例),结果需更大规模研究验证。
- 初步生物标志物分析未发现基线免疫细胞亚群与疗效的显著相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Muscle-invasive bladder cancer (MIBC) with histologic subtypes represents a clinical challenge because of poor responses to conventional therapies and under-representation in clinical trials. This single-center phase 2 trial evaluated the combination of neoadjuvant pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) chemotherapy in patients with pure or predominant nonurothelial histologies. Seventeen patients were enrolled, with squamous differentiation being the most common variant. The primary endpoint, a pathologic complete response (pCR), was achieved in nine of 17 patients (53%), with an additional patient achieving ypTisN0 (downstaging rate 59%) and another achieving a clinical complete response. Grade ≥3 toxicities were observed in 47% of patients, primarily attributable to aMVAC. At median follow-up of 35 mo (range 11-48) the estimated 2-yr event-free survival (EFS) and overall survival rates were 64% (95% confidence interval 32-84%) and 79% (95% confidence interval 47-93%), respectively. Preliminary biomarker analysis did not reveal significant correlations between immune-cell subsets at baseline and pCR or EFS. These findings suggest that chemoimmunotherapy is a very promising approach for MIBC with histology subtypes. Larger studies are warranted to further refine therapeutic strategies.
引用
- Raychaudhuri R, Khaki AR, Redman MW, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. 2025. PMID: 40764177. doi:10.1016/j.eururo.2025.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。